Plain-English translation of NCT07544030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach called pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with standard chemotherapy for advanced ovarian cancer. Half of the participants will receive this new combination treatment, while the other half will receive the standard chemotherapy alone. The study wants to see if delivering chemotherapy directly into the abdomen as a fine mist—along with regular intravenous chemotherapy—helps more patients achieve complete tumor removal during surgery.
Many patients with advanced ovarian cancer have tumors that are too widespread to remove completely with surgery alone, so they need chemotherapy first to shrink the cancer. This trial exists to test whether this new method of delivering medication directly to the affected area might work better than the current standard approach.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new PIPAC treatment combined with standard chemotherapy, or standard chemotherapy alone. The standard chemotherapy involves intravenous infusions given over multiple cycles. If assigned to the experimental group, you will also undergo a minimally invasive procedure to receive the new aerosolized chemotherapy treatment directly into your abdomen. You will have regular check-ups, blood tests, and imaging to monitor your response to treatment and any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China